ENVB
HEALTHCAREEnveric Biosciences Inc
$3.18-0.30 (-8.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENVB Today?
No stock-specific AI insight has been generated for ENVB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.71$17.84
$3.18
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-36.24
Dividend Yield—
Dividend / Share—
ROE-3.0%
Profit Margin—
Debt / Equity—
Trading
Volume445K
Avg Volume (10D)—
Shares Outstanding2.0M
ENVB News
21 articles- Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical ModelYahoo Finance·May 5, 2026
- Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of DirectorsYahoo Finance·Apr 28, 2026
- Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics ForumYahoo Finance·Apr 21, 2026
- Enveric Biosciences Stock Soars After Trump's Psychedelics Executive OrderBenzinga·Apr 20, 2026
- Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 17, 2026
- Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 17, 2026
- Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug CandidatesYahoo Finance·Mar 31, 2026
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025Yahoo Finance·Mar 27, 2026
- Enveric Biosciences Announces Registration of Five TrademarksYahoo Finance·Mar 18, 2026
- Enveric Biosciences Announces Withdrawal of Petition Against Its PatentYahoo Finance·Feb 25, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Feb 23, 2026
- Enveric Biosciences reports EB-003 receptor engagement assay dataYahoo Finance·Feb 20, 2026
- Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay DataYahoo Finance·Feb 19, 2026
- Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and OptionYahoo Finance·Jan 29, 2026
- Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Jan 28, 2026
- Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Jan 28, 2026
- Enveric Biosciences announces issuance of U.S. patentYahoo Finance·Dec 30, 2025
- Enveric Biosciences Announces Patent IssuanceYahoo Finance·Dec 29, 2025
- Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross ProceedsYahoo Finance·Dec 12, 2025
- Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross ProceedsYahoo Finance·Dec 11, 2025
- Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug CandidatesYahoo Finance·Dec 9, 2025
All 21 articles loaded
Price Data
Open$3.74
Previous Close$3.48
Day High$4.60
Day Low$3.70
52 Week High$17.84
52 Week Low$1.71
52-Week Range
$1.71$17.84
$3.18
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-36.24
Dividend Yield—
Dividend / Share—
ROE-3.0%
Profit Margin—
Debt / Equity—
Trading
Volume445K
Avg Volume (10D)—
Shares Outstanding2.0M
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. The company is headquartered in Naples, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—